C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 513/04 (2006.01) A61K 31/38 (2006.01) A61K 31/381 (2006.01) A61K 31/382 (2006.01) A61K 31/395 (2006.01) A61K 31/4035 (2006.01) A61K 31/404 (2006.01) A61K 31/41 (2006.01) A61K 31/427 (2006.01) A61K 31/4355 (2006.01) A61K 31/4365 (2006.01) A61K 31/4375 (2006.01) A61K 31/444 (2006.01) A61K 31/5377 (2006.01) A61P 3/04 (2006.01) A61P 3/10 (2006.01) A61P 5/10 (2006.01) A61P 7/02 (2006.01) A61P 11/06 (2006.01) A61P 17/06 (2006.01) A61P 19/10 (2006.01) A61P 25/00 (2006.01) A61P 25/18 (2006.01) A61P 25/28 (2006
Patent
CA 2323493
The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases) such as PTP1B, CD45, SHP-1, SHP-2, PTP.alpha., LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.
L'invention concerne de nouveaux composés, de nouvelles compositions, des méthodes d'utilisation et des méthodes de fabrication associées. Lesdits composés sont des inhibiteurs de protéine tyrosine phosphatases (PTPases) pharmacologiquement utiles, tels que PTP1B, CD45, SHP-1, SHP-2, PTP.alpha., LAR et HePTP ou analogues. Ces composés sont utiles dans le traitement du diabète du type I, du diabète du type II, de l'intolérance au glucose, de la résistance insulinique, de l'obésité, des dysfonctionnements immunitaires parmi lesquels les maladies auto-immunes entraînant un dysfonctionnement du système de coagulation, des maladies allergiques parmi lesquelles l'asthme, de l'ostéoporose, des troubles proliférants parmi lesquels le cancer et le psoriasis, des maladies entraînant une baisse ou une augmentation de la synthèse ou des effets des hormones de croissance, des maladies entraînant une baisse ou une augmentation de la synthèse des hormones ou cytokines qui régulent la libération d'hormones de croissance ou la réaction à ces hormones, des maladies cérébrales parmi lesquelles la maladie d'Alzheimer et la schizophrénie, et des maladies infectieuses.
Andersen Henrik Sune
Axe Frank Urban
Bakir Farid
Branner Sven
Fogh Iversen Lars
Dimock Stratton Llp
Novo Nordisk A/s
Ontogen Corporation
LandOfFree
Modulators of protein tyrosine phosphatases (ptpases) does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulators of protein tyrosine phosphatases (ptpases), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulators of protein tyrosine phosphatases (ptpases) will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1747071